## Clinical Context This patient presents with hypopigmented, anaesthetic macules and a positive slit-skin smear (AFB-positive), which together confirm **multibacillary (MB) leprosy** per WHO operational classification. The presence of AFB on slit-skin smear is definitive evidence of multibacillary disease, and WHO guidelines mandate immediate initiation of MDT without delay. ## Key Point: **In a confirmed case of leprosy with AFB-positive slit-skin smear, the most appropriate next step is to start WHO-recommended MDT immediately.** For multibacillary leprosy, this is rifampicin 600 mg once monthly (supervised) + dapsone 100 mg daily + clofazimine 300 mg once monthly (supervised) and 50 mg daily, for **12 months**. ## Why Option A is Correct - The diagnosis is already established clinically and microbiologically — no further workup is needed before starting treatment - WHO and NLEP (National Leprosy Eradication Programme) guidelines state that treatment should be initiated as soon as leprosy is diagnosed - Delaying treatment increases the risk of nerve damage, disability, and continued transmission - AFB positivity classifies this as MB leprosy → 12-month MDT regimen is appropriate ## Why Other Options Are Incorrect - **Option B (Nerve palpation before treatment):** While baseline neurological assessment is good clinical practice and should be performed, it is done *as part of* the initial workup and does not constitute the "most appropriate next step" that supersedes starting treatment. In a confirmed MB case, initiating MDT is the priority action per NLEP guidelines. - **Option C (Skin biopsy):** Biopsy is NOT required for routine leprosy management. WHO and NLEP guidelines state that leprosy is a clinical diagnosis; biopsy is reserved for diagnostically uncertain or atypical cases. This patient's diagnosis is already confirmed. - **Option D (Rifampicin monotherapy):** Monotherapy is never appropriate in leprosy due to the risk of drug resistance. MDT is mandatory per WHO guidelines (KD Tripathi, Essentials of Medical Pharmacology, 8th ed.). ## High-Yield: **AFB-positive slit-skin smear = Multibacillary leprosy → 12-month MDT (rifampicin + dapsone + clofazimine).** Per WHO 2018 guidelines and NLEP, treatment should begin immediately upon diagnosis without waiting for biopsy or additional testing. ## Clinical Pearl: The WHO operational classification divides leprosy into **paucibacillary (PB):** ≤5 skin lesions, smear-negative → 6-month MDT (rifampicin + dapsone); and **multibacillary (MB):** >5 lesions OR smear-positive → 12-month MDT (rifampicin + dapsone + clofazimine). A positive slit-skin smear alone classifies a patient as MB regardless of lesion count.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.